Filing Flows › Syndax Pharmaceuticals (SNDX) › Q2 2026
Syndax Pharmaceuticals (SNDX) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 4, 2026
Syndax Pharmaceuticals (SNDX) reported revenue of $72.8M for the second quarter 2026 (Q2 2026), +92% from a year earlier and +12% from the quarter before. Operating margin was -54.9%, net loss $49.4M (67.8% of revenue).
Syndax Pharmaceuticals, Q2 2026: revenue $72.8M (+92% year over year), operating margin -54.9%, net loss $49.4M, operating cash flow −$30.3M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $72.8M | +12% | +92% |
| Operating profit | −$40.0M | — | — |
| Net earnings | −$49.4M | — | — |
| Operating cash flow | −$30.3M | — | — |
What changed
Revenue was $72.8M in Q2 2026, up 92% year over year and up 12% from the previous quarter. Product was the largest line at 75% of revenue. Product added $26.1M year over year (up 91%), 75% of the total change.
Operating costs exceeded revenue by $40.0M, an operating margin of -54.9%. Total costs grew 5% against revenue growth of 92%. The fastest-growing cost line was Other operating costs (+151%). The quarter ended with a net loss of $49.4M, wider than the previous quarter's $42.7M loss.
Operating cash flow was −$30.3M. Non-cash charges added back $5.0M of depreciation and $14.0M of share-based compensation.
Questions
What was Syndax Pharmaceuticals' revenue in the second quarter 2026?
Syndax Pharmaceuticals (SNDX) reported revenue of $72.8M for the second quarter 2026 (Q2 2026), +92% from a year earlier and +12% from the quarter before.
Was Syndax Pharmaceuticals profitable in the second quarter 2026?
Operating loss was $40.0M (-54.9% of revenue) and net loss $49.4M.